Trial Profile

A phase 1 study of REC-3964 in recurrent C. difficile colitis

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs REC-163964 (Primary)
Indications Colitis
Focus Adverse reactions; First in man

Most Recent Events

09 May 2024 According to a Recursion Pharmaceuticals media release, full Phase 1 data from our healthy volunteers study will be presented at the World Congress on Infectious Diseases in Paris in June 2024.
27 Feb 2024 Status changed from recruiting to completed.
08 Aug 2023 According to a Recursion Pharmaceuticals media release, single ascending dose and multiple ascending dose studies are now complete. The company expects to share Phase 1 safety and pharmacokinetics data in Q3 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com